<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538743</url>
  </required_header>
  <id_info>
    <org_study_id>C3421002</org_study_id>
    <nct_id>NCT03538743</nct_id>
  </id_info>
  <brief_title>4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06882961 In Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants
      will receive an investigational product or placebo for 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2018</start_date>
  <completion_date type="Anticipated">February 24, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events</measure>
    <time_frame>Baseline up to 35 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 14 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Baseline up to 14 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to 14 days after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the Concentration-Time Curve</measure>
    <time_frame>Day 1 up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration</measure>
    <time_frame>Day 1 up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration</measure>
    <time_frame>Day 1 up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life</measure>
    <time_frame>Day 1 up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of Drug Recovered Unchanged in Urine</measure>
    <time_frame>Day 28: 0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Cumulative Amount of Drug Recovered Unchanged in Urine</measure>
    <time_frame>Day 28: 0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Renal Clearance</measure>
    <time_frame>Day 28: 0-24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, 0 mg, twice daily, 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 15 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 50 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 150 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 300 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 5, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 6, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 7, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 8, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes treated with a stable dose of metformin at least 500 mg

          -  HbA1c value between 7.0 and 10.5%

        Exclusion Criteria:

        - Type 1 diabetes or secondary forms of diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C3421002&amp;StudyName=A+Phase+1%2C+Randomized%2C+Double-blind%2C+Sponsor-open%2Cplacebo-controlled+Study+To+Assess+The+Safety%2C+Tolerability%2Cpharmacokinetics%2C+And+Pharmacodynamics+Of+Multiple+Escalating+Oral+Doses+Of+Pf-06882961+In+Adult+Subjects+With+Type+2+Diabetes+Mellitus</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C3421002&amp;StudyName=A+Phase+1%2C+Randomized%2C+Double-blind%2C+Sponsor-open%2C+Placebo-controlled+Study+To+Assess+The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+And+Pharmacodynamics+Of+Multiple+Escalating+Oral+Doses+Of+Pf-06882961+In+Adult+Subjects+With+Type+2+Diabetes+Mellitus</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

